Alterity Therapeutics to Host Webcast Today on New Data from the bioMUSE Natural History Study

Core Insights - Alterity Therapeutics is hosting an investor webcast to discuss the bioMUSE Natural History Study results and their implications for the ATH434-202 Phase 2 clinical trial endpoints [1][2]. Group 1: Webcast Details - The webcast will feature CEO Dr. David Stamler and key opinion leader Dr. Daniel Claassen from Vanderbilt University [2]. - The event is scheduled for May 30, 2024, in Australia and May 29, 2024, in the United States, with specific times provided for both regions [2]. Group 2: Company Overview - Alterity Therapeutics is focused on developing treatments for neurodegenerative diseases, with its lead asset ATH434 aimed at treating Parkinsonian disorders [4]. - The company is currently conducting two Phase 2 clinical trials for ATH434 in Multiple System Atrophy [4]. - Alterity is based in Melbourne, Australia, and San Francisco, California, and has a drug discovery platform for neurological diseases [4].